$6.38
2.24% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$6.38
+0.20 3.24% 1M
-9.53 59.90% 6M
-2.33 26.75% YTD
-15.86 71.31% 1Y
-6.21 49.32% 3Y
-9.93 60.88% 5Y
-8.62 57.47% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.14 2.24%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Market capitalization $552.35m
Enterprise Value $-86.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -1.27
P/S ratio (TTM) P/S ratio 8.12
P/B ratio (TTM) P/B ratio 1.41
Revenue (TTM) Revenue $67.99m
EBIT (operating result TTM) EBIT $-203.44m
Free Cash Flow (TTM) Free Cash Flow $110.55m
Cash position $658.19m
EPS (TTM) EPS $-2.09
P/E forward negative
P/S forward 3.69
EV/Sales forward negative
Short interest 9.59%
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
87%
Hold
13%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
68 68
-
100%
- Direct Costs 0.86 0.86
2% 2%
1%
67 67
7,730% 7,730%
99%
- Selling and Administrative Expenses 80 80
44% 44%
118%
- Research and Development Expense 190 190
50% 50%
279%
-203 -203
11% 11%
-298%
- Depreciation and Amortization 0.86 0.86
2% 2%
1%
EBIT (Operating Income) EBIT -203 -203
11% 11%
-299%
Net Profit -182 -182
8% 8%
-268%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
about 17 hours ago
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming investor conferences:
Neutral
GlobeNewsWire
7 days ago
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th –
Neutral
GlobeNewsWire
15 days ago
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today